Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
09 01 2023
Historique:
received: 10 08 2022
revised: 16 11 2022
accepted: 27 11 2022
pubmed: 13 12 2022
medline: 4 1 2023
entrez: 12 12 2022
Statut: ppublish

Résumé

We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE was 89 % (95 % CI 84-93 %) overall, 79 % in patients with more than two comorbidities and 77 % in adults aged 60-75 years. A third dose increased the VE to more than 93 % in all patient-subgroups.

Identifiants

pubmed: 36509640
pii: S0264-410X(22)01489-X
doi: 10.1016/j.vaccine.2022.11.065
pmc: PMC9715487
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

290-293

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. G. received payment/honoraria from Astra Zeneca, Boehringer Ingelheim, Roche Pharma and Berlin Chemie, this had no influence on this work; all other authors reported no conflicts of interest.

Références

Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Front Microbiol. 2021 Jul 01;12:651151
pubmed: 34276587
Clin Infect Dis. 2022 Nov 30;75(11):1980-1992
pubmed: 35438175
Vaccines (Basel). 2022 Feb 11;10(2):
pubmed: 35214737
Virol J. 2021 Jun 2;18(1):110
pubmed: 34078394
Vaccine. 2022 Nov 15;40(48):6979-6986
pubmed: 36374708
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
Front Immunol. 2021 Oct 11;12:714170
pubmed: 34707602

Auteurs

Anna Stoliaroff-Pepin (A)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany. Electronic address: Stoliaroff-PepinA@rki.de.

Caroline Peine (C)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany. Electronic address: PeineC@rki.de.

Tim Herath (T)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.

Johannes Lachmann (J)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.

Delphine Perriat (D)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.

Achim Dörre (A)

Department for Infectious Disease Epidemiology, Robert Koch Institute, Germany.

Andreas Nitsche (A)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Janine Michel (J)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Marica Grossegesse (M)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Natalie Hofmann (N)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Thomas Rinner (T)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Claudia Kohl (C)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Annika Brinkmann (A)

Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.

Tanja Meyer (T)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.

Brigitte G Dorner (BG)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.

Daniel Stern (D)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.

Fridolin Treindl (F)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.

Sascha Hein (S)

Division Virology, Paul-Ehrlich-Institute, Germany.

Laura Werel (L)

Division Virology, Paul-Ehrlich-Institute, Germany.

Eberhard Hildt (E)

Division Virology, Paul-Ehrlich-Institute, Germany.

Sven Gläser (S)

Klinik für Innere Medizin - Pneumologie und Infektiologie, Vivantes Klinikum Neukölln und Spandau, Berlin, Germany.

Helmut Schühlen (H)

Vivantes Netzwerk für Gesundheit GmbH, Direktorat Klinische Forschung & Akademische Lehre, Berlin, Germany.

Caroline Isner (C)

Klinik für Innere Medizin - Infektiologie, Vivantes Auguste-Viktoria-Klinikum, Rubensstr. 125, 12157 Berlin, Germany.

Alexander Peric (A)

Klinik für Pneumologie und Infektiologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin, Germany.

Ammar Ghouzi (A)

Schön Klinik Düsseldorf, Interdisziplinäre Notaufnahme, Am Heerdter Krankenhaus 2, 40549 Düsseldorf, Germany.

Annette Reichardt (A)

Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany.

Matthias Janneck (M)

Klinik für Kardiologie, Sektion Nephrologie, Albertinen Krankenhaus, Süntelstraße 11a, 22457 Hamburg, Germany.

Guntram Lock (G)

Klinik für Innere Medizin, Albertinen Krankenhaus, Süntelstraße 11a, 22457 Hamburg, Germany.

Lars Schaade (L)

Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Germany.

Ole Wichmann (O)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.

Thomas Harder (T)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH